Bio-Rad Life Sciences Q2 Revenues Drop 4 Percent; Digital PCR Sales Slower than Anticipated | GenomeWeb

Bio-Rad this week reported a 4 percent drop in second-quarter revenues for its Life Sciences segment, which includes its traditional endpoint and real-time PCR products as well as its digital PCR products acquired last year along with QuantaLife.

The company recorded a profit of $48.3 million, or $1.69 per share, in Q2 2012 compared to a profit of $40 million, or $1.41 per share in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.